Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEL-CAP: Melphalan with Stem Cell Transplant in CRPC
NCT01907009Phase 3Terminated
- Sponsor
- Barts Health NHS Trust
- Start
- Jan 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melphalan in castration-resistant prostate cancer (CRPC), sponsored by Barts Health NHS Trust. Started Jan 2013; status: terminated.
02
Drugs
melphalan
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01907009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01907009.